Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Depreciation & Amortization (CF) (2016 - 2026)

Pharma-Bio Serv's Depreciation & Amortization (CF) history spans 17 years, with the latest figure at $14796.0 for Q1 2026.

  • For Q1 2026, Depreciation & Amortization (CF) rose 56.75% year-over-year to $14796.0; the TTM value through Jan 2026 reached $65223.0, up 156.14%, while the annual FY2025 figure was $59866.0, 156.81% up from the prior year.
  • Depreciation & Amortization (CF) reached $14796.0 in Q1 2026 per PBSV's latest filing, down from $15817.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $18866.0 in Q2 2025 to a low of $4589.0 in Q3 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $11598.0, with a median of $12800.0 recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 59.75% in 2024, then skyrocketed 243.08% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $12800.0 in 2022, then plummeted by 42.25% to $7392.0 in 2023, then decreased by 19.81% to $5928.0 in 2024, then surged by 166.82% to $15817.0 in 2025, then fell by 6.46% to $14796.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Depreciation & Amortization (CF) are $14796.0 (Q1 2026), $15817.0 (Q4 2025), and $15744.0 (Q3 2025).